Condition: Scleroderma, Systemic · Digital Ulcer · Sponsor: Primus Pharmaceuticals
This study is performed to consider the safety and healing ability of diosmin in patients with systemic sclerosis (scleroderma) and open sores on their fingers (digital ulcers). Two (2) out of three (3) participants will receive active product. The participants will have four (4) visits over eight (8) weeks. Physical exams and photos will be performed. A variety of questions will be asked describing level of pain and lifestyle changes.
This description comes directly from the study's public registry record.
Lukban · (480) 483-1410 · jlukban@primusrx.com
Mary L Sanstead · 480-250-6689 · msanstead@primusrx.com
Always discuss trial participation with your own doctor first.
| University of Calgary | Calgary, Alberta, Canada | Recruiting |
| Dalhousie University | Halifax, Nova Scotia, Canada | Not Yet Recruiting |
| Saint Joseph Health Care Centre | London, Ontario, Canada | Recruiting |
| The Ottawa Hospital | Ottawa, Ontario, Canada | Recruiting |
| Mount Sinai Health System | Toronto, Ontario, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06256575